BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bradbury CA, Craig Z, Cook G, Pawlyn C, Cairns DA, Hockaday A, Paterson A, Jenner MW, Jones JR, Drayson MT, Owen RG, Kaiser MF, Gregory WM, Davies FE, Child JA, Morgan GJ, Jackson GH. Thrombosis in patients with myeloma treated in the Myeloma IX and Myeloma XI phase 3 randomized controlled trials. Blood 2020;136:1091-104. [PMID: 32438407 DOI: 10.1182/blood.2020005125] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 16.0] [Reference Citation Analysis]
Number Citing Articles
1 Wang J, Park C, Arroyo-Suarez R. Venous thromboembolism in patients with multiple myeloma receiving daratumumab-based regimens: a post hoc analysis of phase 3 clinical trials. Leuk Lymphoma 2021;:1-8. [PMID: 33836624 DOI: 10.1080/10428194.2021.1910687] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Santoro M, Romano A, Mancuso S, Siragusa S, DI Raimondo F, Martinelli G, Cerchione C. Prevention of venous thromboembolic events occurring in myeloma patients treated with second-generation novel agents. Panminerva Med 2021;63:1-6. [PMID: 32955183 DOI: 10.23736/S0031-0808.20.04133-6] [Reference Citation Analysis]
3 Rubinstein SM, Tuchman SA. Thrombosis in the modern era of multiple myeloma. Blood 2020;136:1019-21. [DOI: 10.1182/blood.2020006648] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
4 Jackson GH, Pawlyn C, Cairns DA, de Tute RM, Hockaday A, Collett C, Jones JR, Kishore B, Garg M, Williams CD, Karunanithi K, Lindsay J, Rocci A, Snowden JA, Jenner MW, Cook G, Russell NH, Drayson MT, Gregory WM, Kaiser MF, Owen RG, Davies FE, Morgan GJ; UK NCRI Haemato-oncology Clinical Studies Group. Carfilzomib, lenalidomide, dexamethasone, and cyclophosphamide (KRdc) as induction therapy for transplant-eligible, newly diagnosed multiple myeloma patients (Myeloma XI+): Interim analysis of an open-label randomised controlled trial. PLoS Med 2021;18:e1003454. [PMID: 33428632 DOI: 10.1371/journal.pmed.1003454] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Covut F, Ahmed R, Chawla S, Ricaurte F, Samaras CJ, Anwer F, Garcia AVM, Angelini DE, Mazzoni S, Faiman B, Valent J, Khouri J. Validation of the IMPEDE VTE score for prediction of venous thromboembolism in multiple myeloma: a retrospective cohort study. Br J Haematol 2021;193:1213-9. [PMID: 33997961 DOI: 10.1111/bjh.17505] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
6 Jones JR, Pawlyn C, Jackson GH. Safety of lenalidomide for maintenance treatment of patients with multiple myeloma following autologous stem cell transplantation. Expert Opin Drug Saf 2021;:1-9. [PMID: 34184970 DOI: 10.1080/14740338.2021.1945578] [Reference Citation Analysis]
7 Calafiore V, Giamporcaro S, Conticello C, Romano A, Parisi M, Giuffrida G, Tibullo D, Di Raimondo F, Signorelli SS. A Real-Life Survey of Venous Thromboembolic Events Occurring in Myeloma Patients Treated in Third Line with Second-Generation Novel Agents. J Clin Med 2020;9:E2876. [PMID: 32899553 DOI: 10.3390/jcm9092876] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
8 Louzada ML. Thrombosis and myeloma: it is time to get the elephant out of the room. Br J Haematol 2021;193:1027-9. [PMID: 34105140 DOI: 10.1111/bjh.17507] [Reference Citation Analysis]
9 Sanfilippo KM, Carson KR, Wang TF, Luo S, Edwin N, Kuderer N, Keller JM, Gage BF. Evaluation of the Khorana score for prediction of venous thromboembolism in patients with multiple myeloma. Res Pract Thromb Haemost 2022;6:e12634. [PMID: 35028491 DOI: 10.1002/rth2.12634] [Reference Citation Analysis]
10 Ochiai T, Sasaki Y, Yokoyama C, Kuwata H, Hara S. Absence of prostacyclin greatly relieves cyclophosphamide-induced cystitis and bladder pain in mice. FASEB J 2021;35:e21952. [PMID: 34555210 DOI: 10.1096/fj.202101025R] [Reference Citation Analysis]
11 Alam AU, Karkhaneh M, Sun HL, Wu C. Survival patterns among venous thromboembolism patients with hematologic malignancies in Alberta, Canada from 2003 to 2015. Thromb Res 2021;199:59-66. [PMID: 33429125 DOI: 10.1016/j.thromres.2020.12.021] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
12 Miceli TS, Gonsalves WI, Buadi FK. Supportive care in multiple myeloma: Current practices and advances. Cancer Treat Res Commun 2021;29:100476. [PMID: 34653748 DOI: 10.1016/j.ctarc.2021.100476] [Reference Citation Analysis]
13 Barrett A, Quinn J, Lavin M, Thornton P, O'Donnell J, Murphy P, Glavey S. Validation of Risk-Adapted Venous Thromboembolism Prediction in Multiple Myeloma Patients. J Clin Med 2021;10:3536. [PMID: 34441832 DOI: 10.3390/jcm10163536] [Reference Citation Analysis]
14 Diep R, Garcia D. Does aspirin prevent venous thromboembolism? Hematology Am Soc Hematol Educ Program 2020;2020:634-41. [PMID: 33275727 DOI: 10.1182/hematology.2020000150] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
15 Chakraborty R, Rybicki L, Valent J, Garcia AVM, Faiman BM, Khouri J, Samaras CJ, Anwer F, Khorana AA. Arterial thromboembolism in multiple myeloma in the context of modern anti-myeloma therapy. Blood Cancer J 2021;11:121. [PMID: 34172719 DOI: 10.1038/s41408-021-00513-4] [Reference Citation Analysis]
16 Mann H, Katiyar V, Varga C, Comenzo RL. Smoldering multiple myeloma - Past, present, and future. Blood Rev 2021;:100869. [PMID: 34312016 DOI: 10.1016/j.blre.2021.100869] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]